Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Present New Invoice Prices within 3 Days after New NHI Price Announcement: FJPWA
February 20, 2006
- HIV Drug Resistance Measurement Method Developed
February 20, 2006
- Managerial-level Workers at Pfizer Japan Form New Labor Union
February 20, 2006
- Astellas Licenses Prostate Cancer Treatment from Ferring
February 13, 2006
- 3 Switch-OTC Drugs Recommended for Approval
February 13, 2006
- R&D NEW IN BRIEF
February 13, 2006
- SELF-MEDICATION NEWS IN BRIEF
February 13, 2006
- National Burden Rate to Decline to 37.7% in FY2006
February 13, 2006
- Mochida: Moving Ahead with Priority on Profits, Forward-looking Investment
February 13, 2006
- Quintiles Expanding ECG Analysis Service in India
February 13, 2006
- Toho to Seek New Business Challenges Under Next 3-Year Plan
February 13, 2006
- Wako Pure Chemical: New Fecal Occult Blood Analyzer FOBITWAKO
February 13, 2006
- Sucampo Obtains FDA Approval for AMITIZA
February 13, 2006
- DPC Management Study Group Inaugurated
February 13, 2006
- BUSINESS NEWS IN BRIEF
February 13, 2006
- Korosho Announces Nutrition and Weight Gain GL for Pregnant, Nursing Mothers
February 13, 2006
- Focus on Pollinosis (2)
February 13, 2006
- JGPMA to Talk with JPMA About Job Sharing
February 13, 2006
- 2006 Pollen Websites
February 13, 2006
- Nationwide Delivery of Generics Is Possible: Mr Nakagawa
February 13, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…